LGD-6972
- Generic Name
- LGD-6972
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C43H46N2O5S
- CAS Number
- 1207989-09-0
- Unique Ingredient Identifier
- 6IJ842I0Z2
- Background
LGD-6972 is under investigation in clinical trial NCT01919684 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus).
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT02250222
- Locations
- 🇺🇸
Medpace Clinical Pharmacology, Cincinnati, Ohio, United States
🇺🇸Clinical Pharmacology of Miami, Inc, Miami, Florida, United States
🇺🇸Celerion, Inc, Tempe, Arizona, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT01919684
- Locations
- 🇺🇸
Medpace Clinical Pharmacology, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath